BooksTestimonialsInterviewsLibraryArticlesShop Here 

Zepatier

Zepatier beats Harvoni, Sovaldi in hep C clinical-data safety showdown: Advera Health Analytics

February 24, 2016 | By

It's still early days for Merck's hep C combo Zepatier, but the drug could be a frontrunner in terms of safety. In a new data analysis, Zepatier turned up proportionally fewer serious side effects than Gilead Sciences' hep C combo treatment Harvoni and its veteran hep C med Sovaldi.

SolvaldiHealthcare informatics firm Advera Health Analytics looked at clinical trial data for the three drugs and found that while Harvoni and Sovaldi's labels have worrisome side effects such as cardiac arrest and suicidal ideation, Zepatier does not have the same side effects listed. Zepatier is less risky than Sovaldi, according to Advera's report, but the drug's safety is on par with Harvoni, Advera said.

Zepatier and Harvoni worked almost equally well in treating individuals in clinical trials who had already undergone treatment. Harvoni was more effective than Zepatier and Sovaldi in patients who hadn't been treated previously, though, according to the report.

Syndicate content